Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (12): 1125-1130.doi: 10.19982/j.issn.1000-6621.20230353
• Special Topic • Previous Articles Next Articles
Received:
2023-10-07
Online:
2023-12-10
Published:
2023-11-27
Contact:
Lu Shuihua, Email: Supported by:
CLC Number:
Wang Jin, Lu Shuihua. Discipline construction of tuberculosis: from clinical resources to medical research-based translational medicine[J]. Chinese Journal of Antituberculosis, 2023, 45(12): 1125-1130. doi: 10.19982/j.issn.1000-6621.20230353
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20230353
[1] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
[2] | 卢水华. 关注结核病共患病已成为公共卫生的需要. 结核与肺部疾病杂志, 2022, 3(4): 255-260. doi:10.19983/j.issn.2096-8493.20220107. |
[3] | Lange C, Aaby P, Behr MA, et al. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis, 2022, 22(1): e2-e12. doi:10.1016/S1473-3099(21)00403-5. |
[4] |
Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacille Calmette-Guérin vaccination against tuberculosis. Health Technol Assess, 2013, 17(37): 1-372, v-vi. doi:10.3310/hta17370.
pmid: 24021245 |
[5] |
Nguipdop-Djomo P, Heldal E, Rodrigues LC, et al. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis, 2016, 16(2): 219-226. doi:10.1016/S1473-3099(15)00400-4.
pmid: 26603173 |
[6] | National Research Council US Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine:Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press (US), 2011. |
[7] | Turnbull C, Scott RH, Thomas E, et al. The 100000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ, 2018, 361: k1687. doi:10.1136/bmj.k1687. |
[8] | All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The “All of Us” Research Program. N Engl J Med, 2019, 381(7): 668-676. doi:10.1056/NEJMsr1809937. |
[9] | Kaiser J. NIH’s ‘precision nutrition’ bet aims for individualized diets. Science, 2021, 371(6529): 552. doi:10.1126/science.371.6529.552. |
[10] |
Denny JC, Collins FS. Precision medicine in 2030-seven ways to transform healthcare. Cell, 2021, 184(6): 1415-1419. doi:10.1016/j.cell.2021.01.015.
pmid: 33740447 |
[11] | CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med, 2018, 379(15):1403-1415. doi:10.1056/NEJMoa1800474. |
[12] | The CRyPTIC Consortium. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. PLoS Biol, 2022, 20(8): e3001721. doi:10.1371/journal.pbio.3001721. |
[13] | Huang H, Wang C, Rubelt F, et al. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat Biotechnol, 2020, 38(10): 1194-1202. doi:10.1038/s41587-020-0505-4. |
[14] | Chen JX, Han YS, Zhang SQ, et al. Novel therapeutic evaluation biomarkers of lipid metabolism targets in uncomplicated pulmonary tuberculosis patients. Signal Transduct Target Ther, 2021, 6(1): 22. doi:10.1038/s41392-020-00427-w. |
[15] |
Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis, 2013, 207(1): 18-29. doi:10.1093/infdis/jis499.
pmid: 22872737 |
[16] | DiNardo AR, Gandhi T, Heyckendorf J, et al. Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. Eur Respir J, 2022, 60(3): 2102263. doi:10.1183/13993003.02263-2021. |
[17] | Heyckendorf J, Marwitz S, Reimann M, et al. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. Eur Respir J, 2021, 58(3): 2003492. doi:10.1183/13993003.03492-2020. |
[18] | Mulenga H, Musvosvi M, Mendelsohn SC, et al. Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. Am J Respir Crit Care Med, 2021, 204(12): 1463-1472. doi:10.1164/rccm.202103-0548OC. |
[19] |
Turner CT, Gupta RK, Tsaliki E, et al. Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study. Lancet Respir Med, 2020, 8(4): 407-419. doi:10.1016/S2213-2600(19)30469-2.
pmid: 32178775 |
[20] | van Doorn CLR, Eckold C, Ronacher K, et al. Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment. EBioMedicine, 2022, 82:104173. doi:10.1016/j.ebiom.2022.104173. |
[21] |
Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis, 2021, 21(3): 354-365. doi:10.1016/S1473-3099(20)30914-2.
pmid: 33508224 |
[22] | Marakalala MJ, Raju RM, Sharma K, et al. Inflammatory signaling in human tuberculosis granulomas is spatially orga-nized. Nat Med, 2016, 22(5):531-538. doi:10.1038/nm.4073. |
[23] |
Huang Z, LaCourse SM, Kay AW, et al. CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics study. Lancet Microbe, 2022, 3(7): e482-e492. doi:10.1016/S2666-5247(22)00087-8.
pmid: 35659882 |
[24] |
Wallis RS, Ginindza S, Beattie T, et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med, 2021, 9(8): 897-908. doi:10.1016/S2213-2600(20)30448-3.
pmid: 33740465 |
[25] | Marks GB, Nguyen NV, Nguyen PTB, et al. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. N Engl J Med, 2019, 381(14): 1347-1357. doi:10.1056/NEJMoa1902129. |
[26] | 中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识. 中国防痨杂志, 2021, 43(9):874-878. doi:10.3969/j.issn.1000-6621.2021.09.004. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||